TWST · Company research
Twist Bioscience Corporation (TWST): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History - Yahoo! Finance Canada | Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| $TWST stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $TWST stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 15, 2026 | neutral | 0 | 0.6 |
| Tax withholding required CFO Adam Laponis to sell 2,462 Twist Bioscience (TWST) shares. - Stock Titan | Tax withholding required CFO Adam Laponis to sell 2,462 Twist Bioscience (TWST) shares. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History - Yahoo! Finance Canada | Twist Bioscience Corporation (TWST) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera | The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential. | View source ↗ | GlobeNewswire Inc. | Oct 12, 2026 | bullish | 1 | 1 |
| Is Twist Bioscience (TWST) Fairly Valued As Its Shares Rebound? - Simply Wall Street | Is Twist Bioscience (TWST) Fairly Valued As Its Shares Rebound? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| A proposed 2,462-share sale at Twist Bioscience (TWST) includes shares to cover an equity-award tax bill. - Stock Titan | A proposed 2,462-share sale at Twist Bioscience (TWST) includes shares to cover an equity-award tax bill. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience (NasdaqGS:TWST) Stock Forecast & Analyst Predictions - Simply Wall Street | Twist Bioscience (NasdaqGS:TWST) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| Cathie Wood’s ARK sells TWST stock, buys RXRX and NTLA - Investing.com | Cathie Wood’s ARK sells TWST stock, buys RXRX and NTLA Investing.com | View source ↗ | Investing.com | Oct 6, 2026 | neutral | 0 | 0.6 |
| Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity | The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals - Timothy Sykes | Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals Timothy Sykes | View source ↗ | Timothy Sykes | Oct 5, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience (TWST) Stock Rallies On AI Drug Discovery Deals And Target Hikes - Timothy Sykes | Twist Bioscience (TWST) Stock Rallies On AI Drug Discovery Deals And Target Hikes Timothy Sykes | View source ↗ | Timothy Sykes | Oct 5, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run - Yahoo Finance | Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen. - TIKR.com | Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen. TIKR.com | View source ↗ | TIKR.com | Sep 25, 2026 | neutral | 0 | 0.6 |
| What Needs To Be True To Buy Twist Bioscience Stock Now? - Yahoo Finance | What Needs To Be True To Buy Twist Bioscience Stock Now? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| What Needs To Be True To Buy Twist Bioscience Stock Now? - Trefis | What Needs To Be True To Buy Twist Bioscience Stock Now? Trefis | View source ↗ | Trefis | Sep 25, 2026 | neutral | 0 | 0.6 |
| A required tax-withholding sale: Twist Bioscience (TWST) HR executive Paula Green sells 294 shares. - Stock Titan | A required tax-withholding sale: Twist Bioscience (TWST) HR executive Paula Green sells 294 shares. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience Stock: 7 Straight Green Days, Up 33% - Trefis | Twist Bioscience Stock: 7 Straight Green Days, Up 33% Trefis | View source ↗ | Trefis | Sep 21, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience (TWST) Stock Could Be 16% Undervalued On DNA Synthesis Market Outlook - Simply Wall Street | Twist Bioscience (TWST) Stock Could Be 16% Undervalued On DNA Synthesis Market Outlook Simply Wall Street | View source ↗ | Simply Wall Street | Sep 19, 2026 | neutral | 0 | 0.6 |
| Twist Bioscience stock rises as investors continue to reward stronger growth outlook and margin progress - Quiver Quantitative | Twist Bioscience stock rises as investors continue to reward stronger growth outlook and margin progress Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.